Report Accompanying National Defense Authorization Act of 2016 to Include Directive about the Use of, page-19

First 19 Last

Share
Profile

Follow
sinbin

1,979 Posts.

50

12/05/15

11:14

Post #: 15261175
Share

Originally posted by pintohoo ↑

morning,

your opinion would be at odds with brokers reports.

your opinion is way way out of whack with all 5 large US investment bank's valuations.

You, of course might be right - and, subjectively of course - you are right.

That said - there are only 3 ways companies can go at this stage of their life - way undervalued - way overvalued - or just in the 'no interest' area.

The market is a very strange animal indeed - it will often put a far larger MC on companies with nothing more than hope.
Ditto - it will place a low MC on companies with a great idea - already developed - what appears to be solid teams and only a few moves to make to be commercially successful.

The truth is that there are very very few like AJX ------------ already commercial - solid hard working teams - honest management and board - extraordinary connections - a market size which beggars belief -high probability of legislation coming in to kill off competition. Huge chance of large government contracts. Already penetrated into every sector it is targeting in material - all within 5 months. Now looking to entirely new industries. On and on.

If AJX had a MC of $500 million now - you could have the same opinion - but, AJX could easily have that MC - and people not raise an eyebrow.

It really is subjective. The brokers reports we have most recently had are so far out of whack now it's ridiculous - and the latest target was over $1.

Given the de-risking since - I would be surprised if their target was not up quite a few notches from that.

have a great day all

Pinto

Expand

Pinto

Could you please elaborate on the 5 investment bank valuations or are you just assuming this, as I am.

AJX Price at posting: 62.5¢ Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 117 more messages in this thread...

First 19 Last

Add AJX (ASX) to my watchlist

(20min delay)
Last 1.1¢		Change 0.000(0.00%)		Mkt cap ! $17.31M

Open	High	Low	Value	Volume
1.1¢	1.1¢	1.1¢	$3.3K	300K

Buyers (Bids)

No.	Vol.	Price($)
5	2072715	0.9¢

Sellers (Offers)

Price($)	Vol.	No.
1.0¢	133	1

View Market Depth

No.	Vol.	Price($)
5	2072715	0.009
3	4111222	0.008
3	349012	0.007
3	544500	0.006
1	300000	0.005

Price($)	Vol.	No.
0.010	133	1
0.011	768054	5
0.013	240000	1
0.014	134311	1
0.015	431158	2

Last trade - 12.31pm 27/09/2024 (20 minute delay)

AJX (ASX) Chart

Report Accompanying National Defense Authorization Act of 2016 to Include Directive about the Use of, page-19

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Report Accompanying National Defense Authorization Act of 2016 to Include Directive about the Use of, page-19

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News